Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence KNPLPSKETIEQEKQAGES
Primary information
sequence IDSeq_4292
Peptide sequenceKNPLPSKETIEQEKQAGES
CancerPDF_ID CancerPDF_ID913, CancerPDF_ID1926, CancerPDF_ID9897,
PMID19795908,21136997,21533267
Protein NameThymosin beta-4,Thymosin beta-4,Thymosin beta-4-like protein 1
UniprotKB Entry NameTYB4_HUMAN,TYB4_HUMAN,TMSL1_HUMAN
FluidPlasma,Serum,Serum
M/Z705.02,2112.06988,705.03
Charge3,1,3
Mass (in Da)NA,NA,NA
fdrNA,NA,NA
Profiling TechniqueLC-MS,LC-MS,LC-MS
Peptide Identification techniqueMALDI-TOF/TOF,LC-MS-MS/MS,LC/MS/MS
Quantification TechniqueLC-MRM (multiple reaction monitoring),LC-ESI-MS,Multiple Reaction Monitoring
Labelled/Label FreeLabelled,Label Free,Label Free
FDRless than 7%,NA,1.49
CancerPDF_ID CancerPDF_ID913, CancerPDF_ID1926, CancerPDF_ID9897,
p-ValueNA,NA,NA
SoftwareFlexAnalysis 3.0 and Biotools 3.0 software,MASCOT(v. 2.2.01),MASCOT
Length19,19,19
Cancer TypeDuctal adenocarcinoma of the pancreas (DAP),Colorectal cancer,Lung adenocarcinoma
DatabaseNCBI refseq Protein Database,SwissProt Database,Swissprot Database (57.4)
ModificationNA,NA,NA
Number of Patients"31normal, 14patients",30 patients and 30 healthy controls,62 lung adenocarcinoma and 30 healthy control
RegulationNA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal"
ValidationNA,Leave One out Cross validation,MRM-based validation of 19 candidates
SensitivityNA,NA,NA
SpecificityNA,NA,NA
AccuracyNA,NA,NA
Peptide AtlasPeptideAtlas
IEDB239614 502874 503099